3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
6
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
pembrolizumab
16
Bevacizumab
12
Carboplatin
10
Nivolumab
8
Pemetrexed
7
Temozolomide
6
Standard of Care
6
Exercise
6
Cetuximab
6
durvalumab
5
atezolizumab
5
Prednisone
5
Cyclophosphamide
5
abemaciclib
4
Paclitaxel
4
Doxorubicin
4
Dexamethasone
4
Cisplatin
4
Blood Specimen Collection
4
temsirolimus
3
enzalutamide
3
dostarlimab
3
daratumumab
3
cabozantinib
3
Sunitinib
3
Rituximab
3
Oxaliplatin
3
Metformin
3
Leucovorin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
elacestrant
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled